Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Enliven Therapeutics, Inc.NASDAQ: ELVN
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$36.05M, compared with -$20.09M a year earlier. Trailing-twelve-month EBITDA was -$121.76M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -16.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$36.05M-11.0% QoQ
- Last fiscal yearDec 2025
- -$103.43M-16.9% YoY
- LTMSep 2026
- -$121.76M-25.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -79.5% | +100.0% | +179.5 pp |
| 1 year | -16.9% | +100.0% | +116.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (103.43M) USD
- Year-over-year change
- -16.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (103.43M) | -16.9% |
| FY2024 | 2024-12-31 | (88.48M) | -24.1% |
| FY2023 | 2023-12-31 | (71.29M) | -90.4% |
| FY2022 | 2022-12-31 | (37.45M) | -52.1% |
| FY2021 | 2021-12-31 | (24.63M) | — |
EBITDA vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's LTM Sep 2026 EBITDA of -$121.76M is the 3rd highest of the 11 companies compared; the peer median is -$139.63M.
- Its year-over-year change of -25.6% is the 9th highest of 11, against a peer median of +2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.07B | +52.6% | +43.2% | 35.5% | |
| LTM Jul 2026 | $1.05B | +28.1% | +53.4% | 43.0% | |
| LTM Sep 2026 | -$121.76M | -25.6% | — | — | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$130.56M | -36.2% | — | — | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
| LTM Mar 2026 | -$145.24M | -14.0% | — | — | |
| LTM Mar 2026 | -$162.5M | +50.0% | — | 74.8% | |
| LTM Mar 2026 | -$220.73M | -23.8% | — | — | |
| LTM Jun 2026 | -$283.83M | +7.4% | — | 2742.3% | |
| LTM Jun 2026 | -$1.69B | -111.6% | — | — | |
| Peer median (excluding ELVN) | -$139.63M | +2.8% | +48.3% | 74.8% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 263K |
| Gross Profit | 0 | 0 | 0 | 0 | (263K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| Selling, General & Admin | 4.29M | 7.77M | 18.96M | 23.78M | 33.8M |
| Operating Expenses | 24.76M | 38.79M | 83.53M | 104.55M | 119.4M |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| EBITDA | (24.63M) | (37.45M) | (71.29M) | (88.48M) | (103.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (24.76M) | (38.79M) | (83.53M) | (104.55M) | (119.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 22K | 1.13M | 11.95M | 15.76M | 15.96M |
| Income Before Tax | (24.74M) | (37.66M) | (71.58M) | (88.79M) | (103.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 232K | 0 |
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| EPS (Diluted) | (3.17) | (6.03) | (2.01) | (1.89) | (1.83) |
| Weighted Avg Shares | 7.81M | 6.25M | 35.55M | 47.07M | 56.66M |
| Weighted Avg Shares (Diluted) | 7.82M | 6.25M | 35.55M | 47.07M | 56.66M |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.